CMV Reactivation in Acute Necrotizing Pancreatitis

Background and Rationale for the Study Acute pancreatitis is one of the frequently encountered systemic diseases presenting with a wide spectrum of presentation ranging from mild disease which has a better outcome compared to severe disease which usually leads to admission to the intensive care unit (ICU), and is associated with high mortality. According to the revised Atlanta classification (2012), acute pancreatitis is now divided into two distinct subtypes, necrotizing pancreatitis and interstitial edematous pancreatitis (IEP), based on the presence or absence of necrosis. In severe acute pancreatitis, inflammation leads to peri-pancreatic fluid collections of which four distinct subtypes are identified. Acute necrotic collections (ANC) and walled-off necrosis (WON) which occur in patients with necrotizing pancreatitis, contain variable amounts of fluid and necrotic debris which can either be sterile or infective. The mortality rates for sterile necrosis remain comparatively low (5%-10%), but superinfection of the necrotic pancreas and peri-pancreatic tissue/ fluid collections increases the mortality rate considerably (20%-30%).

The infected pancreatic necrosum when cultured, usually demonstrates mono-microbial flora in 60-87% of patients and poly-microbial flora in 13-40% of patients. The most common organisms isolated are gram-negative bacteria, mainly Escherichia coli and Klebsiella pneumonia followed by gram-positive bacteria. With the increased use of antibiotic therapies in the ICU the incidence of pancreatic fungal infections is also on the rise. Fungal pancreatic infections, predominantly caused by Candida species, have been identified in up to one-half with a longer hospital stay and a lower one-year survival than patients with bacterial pancreatic infections only.

Traditionally, critically ill patients have been considered immunocompetent but the presence of sepsis and its immunomodulatory effects may lead to reactivation of dormant viral infections. In recent years, Cytomegalovirus (CMV) reactivation in critically ill patients has been recognized with as high as 71% incidence. Sepsis due to its immunomodulatory effects may lead to the reactivation of CMV due to the release of pro-inflammatory cytokines such as TNF-alpha and IL-1beta which has the ability to activate several transcription factors contributing to CMV reactivation. Studies showed that CMV infection in critically ill patients was consistently associated with undetectable IFN-γ T cell responses within the first 2 days of admission to the ICU and that viral load was inversely related to IFN-γ T cell responses. Similar results were found in septic patients who display immune system paralysis, reduced Th1 cell function, increased IL-10 production (anti-inflammatory), and global lymphopenia affecting natural killer cells (NK) quantitatively and qualitatively related to their interferon production.

Studies have documented significantly higher organ failure rates and mortality in critically ill patients with CMV reactivation. In a systematic review to investigate the association between CMV reactivation and clinical outcomes in immunocompetent critically ill patients, including Itwenty-two studies, CMV reactivation was associated with increased ICU mortality, overall mortality, duration of mechanical ventilation, nosocomial infections, and ICU length of stay. CMV reactivation has also been studied in specific critically ill cohorts, exhibiting their impact on mortality. The effect of CMV reactivation on mortality in immunocompetent acute respiratory distress syndrome (ARDS) patients has also been studied. Of 399 ARDS patients, 68 % were CMV seropositive and reactivation occurred in 27 % of them which was associated with overall increased ICU mortality. In another study among the septic shock cohort (329 patients), herpesvirus reactivations were documented in 68% of patients without prior immunodeficiency, and concluded that reactivations could be independently associated with mortality.

However, no studies are currently available investigating CMV reactivation in patients with acute necrotizing pancreatitis (ANP). The investigators aimed to study the prevalence of CMV reactivation and its viral load kinetics in critically ill patients with ANP

Objectives To study the prevalence of Cytomegalovirus (CMV) reactivation and its viral load kinetics in critically ill adult patients with acute necrotizing pancreatitis

Methodology Study design This prospective observational study will be conducted at the Department of Critical Care Medicine in collaboration with the Department of Gastroenterology and Microbiology, SGPGIMS, Lucknow after approval from the Institutional Ethics Committee (IEC).

Study protocol During the study period, all adult ICU patients with the diagnosis of acute necrotizing pancreatitis will be considered for inclusion. As per inclusion and exclusion criteria, these patients will be screened for the presence of Anti CMV IgG antibodies in their blood. If the patient is IgG seropositive and meets inclusion/exclusion criteria then they will be included in the study and followed up for CMV reactivation during their ICU stay. In patients having CMV reactivation, viral load kinetics will be further followed-up for the next 2 weeks.

Sample collection Blood samples: 1.0 ml blood will be collected in an EDTA vial from an existing venous catheter, on a weekly basis to find CMV reactivation during their ICU stay or 10th week of illness (whichever comes first).

Percutaneous drain: If the patient had an abdominal drain in the proximity of the pancreas, 2.0 ml will be collected in a sterile container on a weekly basis to find CMV reactivation during their ICU stay or the 10th week of illness (whichever comes first).

Pancreatic necrosum: If the patient underwent for necrosectomy, then pancreatic necrosum will be collected in a sterile container (single time)

Laboratory analysis ELISA for IgG antibody detection: The serum collected will be tested for IgG antibodies by ELISA as per manufacturer recommendations. (Abbott Laboratories, Abbott Park, IL). The cut-off of will be set at 0.5 WHO IU/ml (Calibrator 2) by the kit's manufacturer. Samples with a concentration higher than 0.5 WHO IU/ml will be considered positive for CMV IgG. All samples will be tested in duplicate.

CMV quantitative real-time PCR:

DNA Extraction: DNA extraction will be performed on 200 μl of a sample using a QIAamp DNA kit (Qiagen, Inc., Valencia, Calif.). Then, 60 μl of Tris (10 mM, pH 8.0) will be used to elute the DNA, and 10 μl of the DNA will be used for each PCR. The extracted DNA will be stored at -800 C for further work.

Quantitative Real-time PCR for virus detection: A 25 μL reaction will be prepared for the detection of CMV by RTPCR utilizing 10 μL of extracted DNA, 12.5 μL of 2X PCR buffer, and 1.5 μL of AgPath RT-PCR Reagents (Thermo Fisher Scientific, Massachusetts USA) and 1 μL Primer and probe sequences described elsewhere. All oligonucleotides will be synthesized and procured from Thermo Fisher Scientific, USA, and thermal cycling will be performed at 95 °C for 3 min and then 40 cycles of 95 °C for 15 s, 58 °C for the 30s using Applied bio system 7500 Real-Time PCR system (Thermo Fisher Scientific, Massachusetts USA). Each test will consist of 5 quantitative control and results will be interpreted accordingly.

Definitions Acute necrotizing pancreatitis: This will be diagnosed on the basis of clinical sign-symptoms / laboratory parameters and the presence of non-enhancing areas of the pancreas on a contrast-enhanced CT (CECT) scan.

CMV reactivation: The cut-off for diagnosing CMV reactivation will be taken as a value of >1000 copies/ml.

Data collections Demographic and relevant clinical characteristics of included patients will be collected on a structured case report form.

Sample size and statistical analysis Among screened acute necrotizing pancreatitis, 95% of patients are expected to have seropositive for IgG. Assuming 50% seropositive (IgG) patients will develop Cytomegalovirus (CMV) reactivation during the ICU stay. Taking a 15% margin of error in the assumed prevalence (i.e. expected range of 35 to 65%), at a two-sided 95% Confidence interval, the estimated sample size is 43. This study is time limited is 18 months and so during the study period all eligible patients will be screened and considered for inclusion in this study. The investigators are expecting about 50 patients.

Descriptive statistics of the continuous variables are to be presented as mean± standard deviation/median (inter-quartile range) while categorical variables in frequency (%) as appropriate. Student's t-test (independent as well as paired-samples t-test as appropriate) or its non-parametric methods to be used to compare the means/medians between the two groups whereas the Chi-square test or Fisher exact test will be used to compare the proportions. The incidences of CMV reactivations will be calculated and this association with demographic and clinical factors to be assessed using univariate as well as multivariate Cox proportional hazard models. A p-value < 0.05 will be considered statistically significant. Statistical package for social sciences, version-23 (SPSS-23, IBM, Chicago, USA), and MedCalc Software will be used for data analysis.